Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/MDMA/Neurological Injury

MDMA for Neurological Injury

1 paper and 0 clinical trials exploring mdma as a treatment for neurological injury.

Compoundempathogen

MDMA

MDMA is a synthetic empathogen that enhances monoamine release, producing prosocial and anxiolytic effects without frank hallucinosis. Two Phase III trials demonstrated significant PTSD symptom reductions, though FDA review raised concerns about blinding, durability, and safety characterisation.

Full MDMA profile
IndicationApproximately 15 million individuals experience a stroke annually, while traumatic brain injuries occur in around 69 million people worldwide each year.

Neurological Injury

Neurological injury encompasses various forms of brain damage resulting from trauma, strokes, or other factors, leading to significant functional impairment. Recent research into psychedelic compounds presents promising avenues for innovative therapeutic interventions aimed at enhancing recovery and alleviating associated psychological conditions such as PTSD and depression.

Full Neurological Injury profile

Academic Research

1 paper
Open Accessindividual

Beliefs and Perceived Barriers Regarding Psychedelic-assisted Therapy in a Pilot Study of Service Members and Veterans With a History of Traumatic Brain Injury

In a pilot sample of 21 service members and veterans with traumatic brain injury, brief psychoeducation significantly increased positive attitudes and interest in psychedelic-assisted therapy (PAT), and most participants supported PAT availability in medical settings if proven beneficial. Participants nonetheless expressed health concerns (long-term effects, losing their mind, personality changes) and logistical barriers (time, transport, cost), indicating the need for targeted education, command support and practical facilitation to ensure access if PAT is approved.

Published
December 24, 2022
Journal
Military Medicine
Authors
Gray, J. C., Murphy, M., Carter, S. E., Johnson, M. W., Wolfgang, A. S., Ro, M. J., Maples-Keller, J. L.

Clinical Trials

0 trials

No clinical trials have been tagged with both MDMA and Neurological Injury yet.

Trials are continuously being added as new studies are registered.

Explore further

Search all MDMA papers Search all Neurological Injury trials Full MDMA profile Full Neurological Injury profile